Seaweed-derived cosmetic compositions

ABSTRACT

A cosmetic composition is disclosed for applying to skin. The composition includes a liquid and dispersed in the liquid: any amount or form of fucoidan, any amount or form of beta glucan; and any amount of a marine extract. When the cosmetic composition is applied to the skin, the appearance of the skin is improved.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation in part application of U.S. patentapplication Ser. No. 17/066,330, filed Oct. 8, 2020, which is acontinuation application of U.S. patent application Ser. No. 16/798,697,filed Feb. 24, 2020, which is a continuation application of U.S. patentapplication Ser. No. 15/988,780, filed May 24, 2018, which is acontinuation application of U.S. patent application Ser. No. 15/349,437(now U.S. Pat. No. 10,004,681), filed Nov. 11, 2016, which is acontinuation application of U.S. patent application Ser. No. 14/683,591(now U.S. Pat. No. 9,579,279), filed Apr. 10, 2015, which is acontinuation application of U.S. patent application Ser. No. 14/268,908,filed May 2, 2014, which is a continuation application of U.S. patentapplication Ser. No. 13/092,856, filed Apr. 22, 2011, which claimspriority to U.S. Provisional Application No. 61/326,871 filed Apr. 22,2010 which are hereby incorporated by reference for all purposes.

BACKGROUND OF THE INVENTION I. Field of Invention

The present invention relates generally to a cosmetic composition andmore particularly to a cosmetic composition containing seaweed forapplication to skin to improve the appearance of the skin.

II. Description of Related Art

The skin is one of the largest organs in the body. Skin is comprised ofthree main layers: the epidermis, the dermis and subcutaneous layers. Atthe outermost part of the epidermis, a layer of dead cells forms what isknown as a stratum corneum layer. The dermis is the middle layer of skinand is comprised of arrangements of collagen fibres, which surround manyspecialized cells and structures. The innermost layer of the skin is thesubcutaneous layer, often called the sub-dermis. The subcutaneous layeris comprised largely of fat and connective tissue and houses largerblood vessels and nerves. Elastin may be found in all layers of theskin, but is most prominent in the dermis layer.

The condition and appearance is a major concern to most people.Enhancing the appearance of the skin is of significant interest for manypeople. The appearance of the skin can be affected by many sourcesincluding environmental conditions such as sun exposure, buildingheating and air conditioning, and air pollution can acceleratedeterioration of the condition and appearance of skin. Additionally,certain diseases can affect the appearance of the skin. Deterioration ofthe appearance of the skin may include, but is not limited to, wrinkles,loss of firmness and elasticity of the skin, age spots, discolorations,and dryness. In addition, individual factors such as diet, stress, ageand genetics may affect the appearance of the skin.

Various compositions and methods for manipulating the appearance of theskin have been reported. For example, international patent application,published under number WO/2004/100889, describes anti-ageing agents,including 3,3′-thiodipropionic acid or derivatives thereof for improvingthe aesthetic appearance of skin. Another method of manipulating thequality of the skin is cosmetic surgery. It has been reported thatseaweed extracts can be incorporated in compositions for use on the skin(see, for e.g., United States patent application 2004/0219124).

SUMMARY OF THE INVENTION

In accordance with one aspect of the invention there is provided acosmetic composition for applying to skin. The composition includes aliquid, and dispersed in the liquid any amount of fucoidan, any amountof beta glucan, and any amount of a marine extract, wherein the cosmeticcomposition improves the appearance of the skin to which the compositionis applied.

The composition may further include water as the liquid. The compositionmay further include the liquid being a glycolic acid-salicylic acidsolution. The composition may further include the liquid being water anda glycolic acid-salicylic acid solution. The composition may furtherinclude the marine extract being any one or more of a green seaweed, abrown seaweed, an exopolysaccharide, or an algae. The composition mayfurther include the marine extract being Ulva lactuta, Alteromonasmaclodeii, Astaxanthin, or Ecklonia cava.

In another aspect of the invention, the composition may include anyamount of tourmaline. In another aspect of the invention, thecomposition may include any amount of volcanic obsidian. In anotheraspect of the invention, the composition may include any amount of Aloebarbadensis. In another aspect of the invention, the composition mayinclude any amount of hydrolyzed pearl nacre. In another aspect of theinvention, the composition may include any amount of chitosan. Inanother aspect of the invention, the composition may include any amountof a phospholipid.

In accordance with another aspect of the invention, the composition mayinclude any amount of glyceryl stearate. In another aspect of theinvention, the composition may include any amount of stearic acid. Inanother aspect of the invention, the composition may include any amountof cetearyl alcohol. In another aspect of the invention, the compositionmay include any amount of ceteareth 20. In another aspect of theinvention, the composition may include any amount of isopropylpalmitate. In another aspect of the invention, the composition mayinclude any amount of ascorbyl polypeptide. In another aspect of theinvention, the composition may include any amount of tocotrienol. Inanother aspect of the invention, the composition may include any amountof tocopheryl acetate. In another aspect of the invention, thecomposition may include any amount of ergocalciferol. In another aspectof the invention, the composition may include any amount of niacinamide.In another aspect of the invention, the composition may include anyamount of ferulic acid. In another aspect of the invention, thecomposition may include any amount of Camellia sinensis. In anotheraspect of the invention, the composition may include any amount ofCentella asiatica. In another aspect of the invention, the compositionmay include any amount of Chamomile matricaria. In another aspect of theinvention, the composition may include any amount of Echinaceaaugustifolia.

In accordance with another aspect of the invention, the composition mayinclude any amount of Ginko biloba. In another aspect of the invention,the composition may include any amount of butylene glycol. In anotheraspect of the invention, the composition may include any amount ofphenoxyethanol. In another aspect of the invention, the composition mayinclude any amount of caprylyl glycol. In another aspect of theinvention, the composition may include any amount of sorbic acid. Inanother aspect of the invention, the composition may include any amountof peg8/SMDI copolymer. In another aspect of the invention, thecomposition may include any amount of superoxide dismutase liposomes. Inanother aspect of the invention, the composition may include any amountof N-acetyl carnitine. In another aspect of the invention, thecomposition may include any amount of alpha lipoic acid. In anotheraspect of the invention, the composition may include any amount ofL-arginine.

In accordance with another aspect of the invention, the composition mayinclude any amount of Glycine soja. In another aspect of the invention,the composition may include any amount of Rumex crispis. In anotheraspect of the invention, the composition may include any amount of Vitisvinifera. In another aspect of the invention, the composition mayinclude any amount of hinokitiol. In another aspect of the invention,the composition may include any amount of retinol. In another aspect ofthe invention, the composition may include any amount of Panax ginseng.In another aspect of the invention, the composition may include anyamount of allantoin. In another aspect of the invention, the compositionmay include any amount of kaolin. In another aspect of the invention,the composition may include any amount of bentonite. In another aspectof the invention, the composition may include any amount of Undariapinnatifida. In another aspect of the invention, the composition mayinclude any amount of diatomite silica. In another aspect of theinvention, the composition may include any amount of n-acetylglucosamine. In another aspect of the invention, the composition mayinclude any amount of phytoplankton. In another aspect of the invention,the composition may include any amount of a member of the Skeletonema.In another aspect of the invention, the composition may include anyamount of a member of the Thalassiosira. In another aspect of theinvention, the composition may include any amount of a member of theChaetocero. In another aspect of the invention, the composition mayinclude any amount of Fucus vesiculosus. In another aspect of theinvention, the composition may include any amount of sodium pCA. Inanother aspect of the invention, the composition may include any amountof magnesium ascorbyl phosphate. In another aspect of the invention, thecomposition may include any amount of epigallocatechin (EGCG). Inanother aspect of the invention, the composition may include any amountof ellagic acid. In another aspect of the invention, the composition mayinclude any amount of sodium citrate. In another aspect of theinvention, the composition may include any amount of tetrasodium EDTA.In another aspect of the invention, the composition may include anyamount of an emollient. In another aspect of the invention, thecomposition may include any amount of a sunscreen. The sunscreen may bean organic sunscreen. The sunscreen may be an inorganic sunscreen. Inanother aspect of the invention, the composition may include any amountof a silicone surfactant. The silicone surfactant may be cyclomethiconeor dimethicone copolyol.

In another aspect of the invention, the composition may include anyamount of a preservative. The preservative may be methylisothiazolinone,cetylsyredinium chloride, silver, benzyl pCA, or polyaminopropylbiguamide. In another aspect of the invention, the composition mayinclude any amount of an aqueous botanical antioxidant. The aqueousbotanical antioxidant may be hydroxytyrosol, rutin, silymarin, turmeric,genistein, apple, green coffee, quercetin, or rosemary. In anotheraspect of the invention, the composition may include any amount of ahumectant. The humectant may be a glycerol, a sorbitol, or a polyol. Inanother aspect of the invention, the composition may include any amountof a thickener. The thickener may be a cosmetic gum. The cosmetic gummay be alginic acid, xanthan gum, cellulose gum, hydroxtethyl cellulose,dextrin, agar, guar gum, phycocolloid, ghatti gum, cellulose ester,modified potato starch, or pectin. In another aspect of the invention,the composition may include any amount of an oligomer. The oligomer maybe iso-olefin, isodecane, hydrogenated polybutene, hydrogenatedpolydecene, polycaprolactone, fibronectin or polyethylene glycol. Inanother aspect of the invention, the composition may include any amountof an amino acid. The amino acid may be present in its natural form. Theamino acid may be a synethetic amino acid.

In another aspect of the invention, the composition may include anyamount of a mineral and its salt. The mineral may be calcium, magnesium,manganese, or zinc. In another aspect of the invention, the compositionmay include any amount of a base. The base may be a soluble plantbutter, a soluble plant wax, an anhydrous plant based cholesterol base,a phycocolloid gel base, a prepared polyethylene glycol ointment base,or a prepared carbomer gel base. In another aspect of the invention, thecomposition may include any amount of a marine component. The marinecomponent may be an Enteromorpha species, a Porphyra species, a Chrondusspecies, a Laminares species, a kelp species or a Fucals species. Inanother aspect of the invention, the composition may include any amountof an anti-inflammatory agent. The anti-inflammatory agent may beGlycyrrhiza glabria, Boswellia serrata, Curcuma longa, turmeric, Arnicamontana, silymarin, water melon, calendula, eidelweiss, or ginger. Inanother aspect of the invention, the composition may include any amountof a surfactant. The surfactant may be amphoteric. The surfactant may becocomidopropyl betaine. The surfactant may be non-ionic. The surfactantmay be cocoglucoside or coco polyglucose. The surfactant may becationic. The surfactant may be lauryl dimoniumhydrolysed collagen.

In another aspect of the invention, the composition may include anyamount of a percutaneous penetration enhancer. The percutaneouspenetration enhancer may be polyethylene glycol or oleic acid. Inanother aspect of the invention, the composition may include any amountof a preservative enhancer. The preservative enhancer may be ethylhexylglycerin, benzethonym chloride, or a hydantoin/PCB blend. In anotheraspect of the invention, the composition may include any amount of avasodilator. The vasodilator may be adenosine triphosphate or liposomal1 arginine. In another aspect of the invention, the composition mayinclude any amount of a vasoconstrictor. The vasoconstrictor may be seabuckthorn, milk thistle, or marshmallow root. In another aspect of theinvention, the composition may include any amount of a whitening agent.In another aspect of the invention, the composition may include anyamount of a tyrosinase inhibitor. The tyrosinase inhibitor may beselected from the Glycyrrhiza species. The tyrosinase inhibitor may be afavnoid, a polyphenol, an isoflavone, a seaweed extract, or a coumarin.In another aspect of the invention, the composition may include anyamount of octadecnedioic acid. In another aspect of the invention, thecomposition may include any amount of chalcones.

Other aspects and features of the present invention will become apparentto those ordinarily skilled in the art upon review of the followingdescription of specific embodiments of the invention.

DETAILED DESCRIPTION

Any terms not directly defined herein shall be understood to have themeanings commonly associated with them as understood within the art ofthe invention. Certain terms are discussed below, or elsewhere in thespecification, to provide additional guidance to the practitioner indescribing the compositions, devices, methods and the like ofembodiments of the invention, and how to make or use them. It will beappreciated that the same thing may be said in more than one way.Consequently, alternative language and synonyms may be used for any oneor more of the terms discussed herein. No significance is to be placedupon whether or not a term is elaborated or discussed herein. Somesynonyms or substitutable methods, materials and the like are provided.Recital of one or a few synonyms or equivalents does not exclude use ofother synonyms or equivalents, unless it is explicitly stated. Use ofexamples in the specification, including examples of terms, is forillustrative purposes only and does not limit the scope and meaning ofthe embodiments of the invention herein.

In accordance with one aspect of the invention there is provided acosmetic composition for applying to skin. The composition is comprisedof a liquid and dispersed in the liquid is any amount or type offucoidan, any amount or type of beta glucan, and any amount of a marineextract. Beta glucan can be derived from a yeast extract or, forexample, from a mushroom. When applied to the skin, the cosmeticcomposition improves the appearance of the skin. Improved appearance ofthe skin may be associated with any one of the following but is notlimited to the following: decreased skin wrinkles, increased skinsmoothness, decreased roughness of the skin, increased Luminosity of theskin, increased clarity of the skin, increased firmness of the skin,increased tautness of the skin, decreased irritation of the skin,decreased skin-associated inflammation, improved skin tone, improvedhydration of the skin, decreased dryness of the skin, improvements inskin discoloration, and decreased breakouts of skin conditions such asacne.

Optionally, the liquid may be water, and can include but is not limitedto distilled water. Optionally, the liquid may be a glycolicacid-salicylic acid solution. Further, and optionally, the liquid may bea combination of water, including but not limited to distilled water,and a glycolic acid-salicylic acid solution. Optionally, the marineextract used in the combination may include one or more of a greenseaweed, a brown seaweed, an exopolysaccharide, or an algae. A greenseaweed may include but is not limited to the Ulva genus andparticularly Ulva lactuta. A brown seaweed may include but is notlimited to laminariales, which is commonly known as kelp and fucals. Abrown seaweed may include Ecklonia cava. An expolysaccharide isunderstood to be a high-molecular-weight polymer of sugar residues.Algae may include but are not limited to members of the followinggroups: Archaeplastida, Rhizaria, Excavata, Excavata, Chromista, andAlveolata. Optionally, the composition may include a marine extractselected from Ulva lactuta, Undaria pinnatifida, Fucus vesiculosus,Alteromonas maclodeii, Astaxanthin, or Ecklonia cava.

Optionally, the composition may include any amount of tourmaline.Optionally, the composition may include any amount of volcanic obsidian.The composition may include any amount of Aloe barbadensis. Thecomposition may further include any amount of hydrolyzed pearl nacre.Optionally, the composition may include any amount of chitosan.Optionally, the composition may include any amount of a phospholipid. Aphospholipid is understood as being any of a variety ofphosphorous-containing lipids that are composed mainly of fatty acids, aphosphate group, and a simple organic molecule. Optionally, thecomposition may include any amount of glyceryl stearate. Optionally, thecomposition may include any amount of stearic acid. Optionally, thecomposition may include any amount of cetearyl alcohol.

Further, the composition may include any amount of ceteareth 20. Thecomposition may also include any amount of isopropyl palmitate.Optionally, the composition may include any amount of one or more of thefollowing: ascorbyl polypeptide, tocotrienol, tocopheryl acetate,ergocalciferol, niacinamide, or ferulic acid. Optionally, thecomposition may include any amount of Camellia sinensis. Further, thecomposition may include any amount of one or more of the following:Centella asiatica, Chamoniile matricaria, Echinacea augustifolia, orGinko biloba. Optionally, the composition may include any amount of oneor more of the following: butylene glycol, phenoxyethanol, caprylylglycol, sorbic acid, peg8/SMDI copolymer, superoxide dismutaseliposomes, N-acetyl carnitine, alpha lipoic acid, or 1-arginine.

Further, the composition may include any amount of one or more of thefollowing: Glycine soja, Rumex crispis, Vitis vinifera, hinokitiol,retinol, Panax ginseng, allantoin, kaolin, bentonite, Undariapinnatifida, diatomite silica, or n-acetyl glucosamine. The compositionmay further include any amount of a phytoplankton species. Thecomposition may include any amount of a member of the Skeletonema. Thecomposition may include any amount of a member of the Thalassiosira. Thecomposition may include any amount of a member of the Chaetoceros.

Further, the composition may include any amount of Fucus vesiculosus.The composition may include any amount of one or more of the following:sodium pCA, magnesium ascorbyl phosphate, epigallocatechin (EGCG),ellagic acid, sodium citrate, or tetrasodium EDTA. The composition mayinclude any amount of an emollient. An emollient is understood as beinga material used for the prevention or relief of dryness, as well as forthe protection of the skin.

The composition may include any amount of a sunscreen. The sunscreen maybe an organic sunscreen. According to an embodiment of the invention,the composition may include from approximately 0.1 to approximately 10%,and preferably from approximately 1 to approximately 5% by weight of anorganic sunscreen material. The sunscreen may be an inorganic sunscreen.According to an embodiment of the invention, the composition may includean inorganic sunscreen such as titanium dioxide or zinc oxide, having anaverage particle size of from I to 300 nm, or iron oxide, having anaverage particle size of from 1 to 300 nm, or silica, having an averageparticle size of from 1 to 100 nm.

The composition may include any amount of a silicone surfactant, whichmay include but is not limited to cyclomethicone or dimethiconecopolyol. The composition may include any amount of a preservative.Examples of a preservative include but are not limited tomethylisothiazolinone, cetylsyredinium chloride, silver, benzyl pCA, orpolyaminopropyl biguamide.

Further, the composition may include any amount of an aqueous botanicalantioxidant. Examples of an aqueous botanical antioxidant include, butare not limited to, hydroxytyrosol, rutin, silymarin, turmeric,genistein, apple, green coffee, quercetin, or rosemary. Further, thecomposition may include any amount of a humectant. The humectant may bea glycerol, a sorbitol, or a polyol. The humectant chosen is not limitedto the foregoing list of humectants.

The composition may include any amount of a thickener, including but notlimited to, a cosmetic gum. The cosmetic gum may include, but is notlimited to, alginic acid, xanthan gum, cellulose gum, hydroxtethylcellulose, dextrin, agar, guar gum, phycocolloid, ghatti gum, celluloseester, modified potato starch, or pectin. Further, the composition mayinclude any amount of an oligomer, including but not limited to, anoligomer of iso-olefin, isodecane, hydrogenated polybutene, hydrogenatedpolydecene, polycaprolactone, fibronectin or polyethylene glycol. Anoligomer is understood as representing a few of the aforementionedmonomeric units.

The composition may include any amount of an amino acid. The amino acidmay be in its natural form or it may be a synthetic amino acid. An aminoacid may be described as, for example, polar, non-polar, acidic, basic,aromatic or neutral. A polar amino acid is an amino acid that mayinteract with water by hydrogen bonding at biological or near-neutralpH. The polarity of an amino acid is an indicator of the degree ofhydrogen bonding at bio logical or near-neutral pH. Examples of polaramino acids include serine, proline, threonine, cysteine, asparagine,glutamine, lysine, histidine, arginine, aspartate, tyrosine andglutamate. Examples of non-polar amino acids include glycine, alanine,valine leucine, isoleucine, methionine, phenylalanine, and tryptophan.Acidic amino acids have a net negative charge at a neutral pH. Examplesof acidic amino acids include aspartate and glutamate. Basic amino acidshave a net positive charge at a neutral pH. Examples of basic aminoacids include arginine, lysine and histidine. Aromatic amino acids aregenerally nonpolar, and may participate in hydrophobic interactions.Examples of aromatic amino acids include phenylalanine, tyrosine andtryptophan. Tyrosine may also participate in hydrogen bonding throughthe hydroxyl group on the aromatic side chain. Neutral, aliphatic aminoacids are generally nonpolar and hydrophobic. Examples of neutral aminoacids include alanine, valine, leucine, isoleucine and methionine. Anamino acid may be described by more than one descriptive category. Aminoacids sharing a common descriptive category may be substitutable foreach other in a peptide.

An amino acid residue may be generally represented by a one-letter orthree-letter designation, corresponding to the trivial name of the aminoacid, in accordance with the following Table A.

Amino acids comprising the peptides described herein will be understoodto be in the L- or D-configuration. Amino acids described herein, may bemodified by methylation, amidation, acetylation or substitution withother chemical groups which may change the circulating half-life of thepeptide without adversely affecting their biological activity.Additionally, a disulfide linkage may be present or absent in thepeptides of the invention.

Nonstandard amino acids may occur in nature, and may or may not begenetically encoded. Examples of genetically encoded nonstandard aminoacids include selenocysteine, sometimes incorporated into some proteinsat a UGA codon, which may normally be a stop codon, or pyrrolysine,sometimes incorporated into some proteins at a UAG codon, which maynormally be a stop codon. Some nonstandard amino acids that are notgenetically encoded may result from modification of standard amino acidsalready incorporated in a peptide, or may be metabolic intermediates orprecursors, for example. Examples of nonstandard amino acids include4-hydroxyproline, 5-hydroxylysine, 6-N-methyllysine,gamma-carboxyglutamate, desmosine, selenocysteine, omithine, citrulline,lanthionine, 1-aminocyclopropane-1-carboxylic acid, gamma-aminobutyricacid, camitine, sarcosine, or N-formylmethionine. Synthetic variants ofstandard and non-standard amino acids are also known and may includechemically derivatized amino acids, amino acids labeled foridentification or tracking, or amino acids with a variety of side groupson the alpha carbon. Examples of such side groups are known in the artand may include aliphatic, single aromatic, polycyclic aromatic,heterocyclic, heteronuclear, amino, alkylamino, carboxyl, carboxamide,carboxyl ester, guanidine, amidine, hydroxyl, alkoxy, mercapto-,alkylmercapto-, or other heteroatom-containing side chains.

TABLE A Nomenclature and abbreviations of the 20 standard L-amino acidscommonly found in naturally occurring peptides Three-letter One-letterFull name abbreviation abbreviation Alanine Ala A Cysteine Cys CAspartic acid Asp D Glutamic acid Glu E Phenylalanine Phe F Glycine GlyG Histidine His H Isoleucine Ile I Lysine Lys K Leucine Leu L MethionineMet M Asparagine Asp N Proline Pro P Glutamine Gln Q Arginine Arg RSerine Ser S Threonine Thr T Valine Val V Tryptophan Trp W Tyrosine TyrTOther synthetic amino acids may include alpha-amino acids, non-alphaamino acids such as beta-amino acids, des-carboxy or des-amino acids.Synthetic variants of amino acids may be synthesized using generalmethods known in the art, or may be purchased from commercial suppliers,for example RSP Amino Acids LLC (Shirley, Mass.).

Additionally, the composition may include any amount of a mineral andits salt. The mineral may be calcium, magnesium, manganese, or zinc. Themineral chosen is not limited to the aforementioned minerals. Thecomposition may include any amount of a base, including but not limitedto, a soluble plant butter, a soluble plant wax, an anhydrous plantbased cholesterol base, a phycocolloid gel base, a prepared polyethyleneglycol ointment base, or a prepared carborner gel base. The compositionmay include any amount of a marine component including, but not limitedto, any one or more of the following: an Entermnorpha species, aPorphyra species, a Chrondus species, a Larninares species, a kelpspecies or a Fucals species. Further, the algae utilized herein may be abrown seaweed, a red seaweed, or a green seaweed. The seaweeds may beselected based on their content of natural amino acids, fatty acids(ceramides) and their glycosyl derivatives, sterols, naturalantimicrobials, ursolic acid, and moo/polysacchar ides.

Further, the composition may include any amount of an anti-inflammatoryagent. The anti-inflammatory agent may include, but is not limited to,any one or more of the following: Glycyrrhiza glabria, Boswelha serrate,Curcuma longa, turmeric, Arnica niontana, silymarin, water melon,calendula, eidelweiss, or ginger.

The composition may include any amount of a surfactant. The surfactantmay be amphoteric. They surfactant may be, but is not limited to,cocomidopropyl betaine. The surfactant may be non-ionic. The surfactantmay be, but is not limited to, cocoglucoside or coco polyglucose. Thesurfactant may be cationic. The surfactant may be, but is not limitedto, lauryl dirnoniumhydrolysed collagen.

The composition may include any amount of a percutaneous penetrationenhancer including, but not limited to, any one or more of thefollowing: polyethylene glycol or oleic acid. The composition mayinclude any amount of a preservative enhancer including, but not limitedto, any one or more of the following: ethylhexyl glycerin, benzethonymchloride, or a hydantoin/PCB blend. Further, the composition may includeany amount of a vasodilator including, but not limited to, any one ofthe following: adenosine triphosphate or liposomal 1 arginine.

Further, the composition may include any amount of a vasoconstrictorincluding, but not limited to, any one or more of the following: seabuckthorn, milk thistle, or marshmallow root. Additionally, thecomposition may include any amount of a whitening agent. The compositionmay include any amount of a tyrosinase inhibitor including, but notlimited to, an inhibitor selected from the Glycyrrhiza species. Thetyrosinase inhibitor may include, but is not limited to, a favnoid, apolyphenol, a seaweed extract, an isoflavone, or a coumarin. Further,the composition may include any amount of octadecnedioic acid orchalcones or a combination thereof.

Although the foregoing invention has been described in some detail byway of illustration and example for purposes of clarity ofunderstanding, it will be readily apparent to those of skill in the artin light of teachings of this invention that changes and modificationmay be made thereto without departing from the spirit or scope of theinvention. All patents, patent applications, and other publicationsreferred to herein are hereby incorporated by reference.

EXAMPLES Example 1. Composition with Acidified Fucoidan, Beta Glucan,and Ascorbyl Polypeptide

In accordance with an embodiment of the present invention, a compositionis described having the components shown in Table 1 below. Themethodology employed in producing the composition using the amountsdescribed in Table 1 below is generally as follows.

Method Sequence No. 1

In a first mixture, neutralized glycolic and salicyclic acid solution(source: Spectrum Chemical; Gardena, Calif.) was heated in a stainlesssteel container to approximately 85 degrees Celsius. The seaweed complexconsisting of Ulva Lactuta, Alteronwnas rnaclodeii, and astaxanthin(source: Unipex Innovations, Mississauga, Ontario) was added to theheated glycolic acid mixture. The combined mixture was mixed forapproximately 45 to 60 minutes.

TABLE 1 Components of an embodiment of the invention Se- Amount quence(% by No. Component weight) I Glycolic acid-salicylic acid solution(ratio: 8:1) 10 (neutralized with ammonium hydroxide; ammoniumglycolate, sodium lactate can also be added to obtain a preferable pH of~4) I Seaweed complex containing Ulva lactuta, 5.5 Alteromonas maclodeiiand Astaxanthin (ratio: 7:1.5:1.5) I Distilled Water 20.8 I Tourmaline(0.15%) and volcanic obsidian (0.05%) 0.2 I Beta glucan (yeast andspecified medicinal fungi 8 extract combined in a 1:1 ratio) andfucoidan complex (beta glucan and fucoidan are present in a 1:1 ratio) IAqueous Aloe barbadensis extract 10 I Hydrolyzed pearl nacre (1.5%) andchitosan (0.5%) 2.5 I Phospholipids 10 II Glyceryl stearate, stearicacid, cetearyl alcohol, 15 ceteareth 20, isopropyl palmitate complex(each of these products is added at an equal amount) II Ascorbylpolypeptide, tocotrienol, tocopheryl acetate, 6 ergocalciferol,niacinamide complex (ratio of these products: 3:1:1:1:1:1) II Aqueousextract of Camellia sinensis, Centella 1.5 asiatica, Chamomilematricaria, Echinacea augustifolia, Ginko biloba (each of these productsis added at an equal amount) III Complex of butylene glycol,phenoxyethanol, 2.5 caprylyl glycol, sorbic acid, peg8/SMDI copolymer(these products are added at the following ratio:1.5:0.5:0.25:0.25:0.25) III Aqueous superoxide dismutase liposomes 8

A polarized water was developed by adding tourmaline and obsidian(source: Soliance; Paris, France) to the distilled water. The betaglucan (source: Biothera; Eagen, Minn.) and fucoidan (source: Marinova;Cambridge, Tasmania, Australia) complex was dissolved in one-third ofthe polarized water. The dissolved beta glucan-fucoidan complex wasadded to the glycolic acid mixture (previously described above) and theentire solution was maintained at approximately 85 degrees Celsius forapproximately 30 minutes. While maintaining mixing of the mixture,aqueous Aloe barbedensis leaf extract (source: Tri K Industries;Northvale, N.J.) was added and the entire mixture was allowed to coolfor approximately 30 minutes. Thereafter, hydrolyzed pearl nacre(source: Active Concepts; Lincolnton, N.C.) and chitosan (source: AlfaChem; Kings Point, N.Y.) were added to the cooled mixture. The entiremixture was allowed to cool to approximately 30 degrees Celsius.Thereafter, phospholipids (source: Arch Personal Care; Norwalk, Conn.)were added to the cooled mixture.

Method Sequence No. 2

In a further mixture, glycerylstearate, stearic acid, cetearyl alcohol,ceteareth 20, and isopropyl palmitate complex (source: Hallstar Corp.;Chicago, Ill.) were heated to 75 degrees Celsius in a 200 kg stainlesssteel vat. The mixture was mixed by continuous stirring forapproximately 60 minutes.

Separately, the remaining two-thirds of polarized water (as describedabove) was used to dissolve the ascorbyl po lypeptide-tocotrienolcomplex (source: Arch Personal Care). The ascorbylpolypeptide-tocotrienol complex was allowed to dissolve in the polarizedwater for approximately one hour. Thereafter, aqueous extracts ofCamellia sinensis, Centella asiatica, Chamomile matricaria, Echinaceaaugustifolia, and Ginko biloba (source: Active Organics; Louisville,Tex.) were added to the ascorbyl polypeptide-tocotrienol complex.

Method Sequence No. 3

In a further mixture, butylene glycol, phenoxyethanol, caprylyl glycol,sorbic acid, and peg8/SMDI copolymer were added at the ratio describedabove to make a complex (source: International Specialty Products;Mississauga, Ontario). Thereafter, this complex was added to theglyceryl stearate complex mixture described above, the glyceryl stearatecomplex having been maintained at approximately 75 degrees Celsius.Thereafter, the ascorbyl polypeptide-tocotrienol complex, which hadpreviously been mixed with the aqueous extracts described above, wasadded and agitation of the mixture continued at approximately 75 degreesCelsius. Thereafter, the entire mixture was cooled down to approximately30 degrees Celsius.

Thereafter, the mixture developed from Method Sequence No. 1 was addedto the mixture. The mixture was allowed to cool down to approximately 20degrees Celsius and liposomal superoxide dismutase (source: ArchPersonal Care) was added.

In a modification to the above, the seaweed complex can be present as1.5% of the formulation instead of 5.5% as described in Table 1.Further, the beta glucan and fucoidan complex can be present as 12% ofthe formulation instead of 8% as described in Table 1.

Testing Efficacy of Example 1

To test the efficacy of the mixture described in Example 1, the mixturewas used by human subjects to determine the effect on the appearance oftheir skin. The results routinely showed that following application ofthe mixture described in Example 1, the human subjects exhibitedimproved appearance of their skin.

Serving as an example, JT, a female under the age of 30 years of age,used the formulation defined in Example 1. Prior to using theformulation of Example 1, JT had exhibited sensitive skin and a tendencyto have acne breakouts. JT also described numerous fine lines beingvisible in her forehead region. On day 0, JT began using an amountapproximately equivalent to the size of a quarter and used approximatelythat amount each morning on her skin. After one week, JT described herskin as being brighter and with an improved complexion. After two weeks,JT described that the fine lines on her skin were blurred. After onemonth, JT described that her skin had less breakouts and was verysmooth. JT identified at least the following attributes as beingassociated with the formulation defined in Example 1: increasedsmoothness and brightness of the skin, decreased lines on JT's forehead,and decreased breakouts of acne. Further, JT identified the formulationof Example 1 as being associated with decreased dryness of the skin.

Example 2. Composition with Non-Acidified Fucoidan and Beta Glucan

In accordance with a further embodiment of the present invention, acomposition is described having the components shown in Table 2. Themethodology employed in producing the composition using the amountsdescribed in Table 2 is generally as follows.

Method Sequence No. 1

In a first mixture, a polarized water was developed by adding tourmalineand obsidian (source: Soliance) to the distilled water. The seaweedcomplex consisting of Ulva lactuta, Astaxanthin, Alteronionas maclodeii(source: Unipex Innovations; Quebec City, Quebec) was dissolved into onehalf of the polarized water. The mixture was maintained at approximately85 degrees Celsius. While maintaining the temperature, the mixture wasstirred for approximately 45 minute s to 60 minutes. Thereafter, betaglucan (source: Biothera) and fucoidan (source: Marinova) complex weredissolved in the seaweed complex-distilled water mixture. This mixturewas maintained at approximately 85 degrees Celsius and the mixture wasstirred for at least approximately 30 minutes.

Thereafter, while maintaining the mixing of the mixture, the aqueousAloe barbedensis leaf extract (source: Tri K Industries) was added andthe entire mixture was allowed to cool for approximately 30 minutes.

Thereafter, hydrolyzed pearl nacre (source: Rita Corp.; Crystal Lake,Ill.) and chitosan (source: Alfa Chem), acetyl glucosomine (source: AlfaChem), n-acetyl carnatine (source: Alfa Chem), alpha lipoic acid(source: Alfa Chem), and I-arginine (source: Alfa Chem) were added tothe cooled mixture. The cooled mixture was further cooled toapproximately 30 degrees Celsius. Thereafter, phospholipids (source:Arch Personal Care) and sodium hyaluronate (source: Tri-K Industries)were added to the mixture.

Method Sequence No. 2

In a second mixture, glyceryl stearate, stearic acid, cetearyl alcohol,ceteareth 20, isopropyl palmitate complex (all from source: HallstarCorp.) were heated to 75 degrees Celsius in a 200 kg. stainless steelvat. The mixture was mixed by continuous stirring for approximately 60minutes.

TABLE 2 Components of an embodiment of the invention Se- Amount quence(% by No. Component weight) I Distilled water 18.8 I Tourmaline (0.15%)and volcanic obsidian (0.05%) 0.2 I Seaweed complex containing Ulvalactuta, 10 Astaxanthin, Alteromonas maclodeii (ratio of these products:7:1.5:1.5) I Beta glucan (yeast and specified medicinal fungi 10 extractcombined in a 1:1 ratio) and fucoidan complex (beta glucan and fucoidanare present in a 1:1 ratio) I Aqueous Aloe barbedensis leaf extract 12 IHydrolyzed pearl nacre and chitosan (ratio of these 1.5 products: 1.5:1)I N-acetyl carnitine, alpha lipoic acid, and l-arginine 3.5 (ratio ofthese products: 1.5:1.5:0.5) I Phospholipids and sodium hyaluronate(ratio of these 8 products: 4:1) II Glyceryl stearate, stearic acid,cetearyl alcohol, 15 ceteareth 20, isopropyl palmitate complex (each ofthese products is added at an equal amount) II Ascorbyl polypeptide,tocotrienol, tocopheryl acetate, 5 ergocalciferol, ferulic acid,niacinamide complex (ratio of these products: 3:1:0.5:0.5:0.5:0.5) IIGlycine soja, Rumex crispis, Vitis vinifera, hinokitiol 2 (betathujaplicin) (each of these products is added at an equal amount) IIAqueous extract of Camellia sinensis, Centella 2.5 asiatica, Chamomilematricaria, Echinacea augustifolia, Ginko biloba (each of these productsis added at an equal amount) III Complex of butylene glycol,phenoxyethanol, 3.5 caprylyl glycol, sorbic acid, peg8/SMDI copolymer(ratio of these products: 1.5:0.5:0.25:0.25:0.25) III Aqueous superoxidedismutase liposomes 8

Separately, ascorbyl polypeptide, tocotrienol, tocopheryl acetate,ergocalciferol, ferulic acid, and niacinamide (all from source: ArchPersonal Care) were dissolved into the second half of the polarizedwater (as described above) over a period of approximately one hour.Thereafter, Glycine soja, Rumex crispis, Vitis vinifera, and hinokitiol(beta thujaplicin) (all from source: Active Organics); and aqueousextracts of Camellia sinensis, Centella asiatica, Chamomile matricaria,Echinacea augusnfolia, and Ginko biloba (all from source: ActiveOrganics) were added to the ascorbyl polypeptide-tocotrienol mixture.

Method Sequence No. 3

Butylene glycol, phenoxyethanol, caprylyl glycol, sorbic acid andpeg8/SMDI copolymer (all from source: International Specialty Products)were combined to form a complex. Thereafter, the complex was added tothe glyceryl stearate mixture described above, while the glycerylstearate mixture was maintained at approximately 75 degrees Celsius.Thereafter, the ascorbyl polypeptide-tocotrienol mixture described abovewas added and agitation of the mixture continued at approximately 75degrees Celsius. The entire mixture was then cooled to approximately 30degrees Celsius. Thereafter, the mixture developed above in MethodSequence No. 1 was added. Thereafter, the mixture was allowed to cool toapproximately 20 degrees Celsius and liposomal superoxide dismutase(source: Arch Personal Care) was added.

In a modification to the above, the seaweed complex can be present as 4%of the formulation instead of 10% as described in Table 2. Further, thebeta glucan and fucoidan complex can be present as 16% of theformulation instead of 10% as described in Table 2.

Testing Efficacy of Example 2

To test the efficacy of the mixture described in Example 2, the mixturewas used by human subjects to determine the effect on the appearance oftheir skin. The results routinely showed that the mixture described inExample 2 improved the appearance of the skin of human subjects.

Serving as an example, MJ, a female over the age of 40 years of age,used the formulation defined in Example 2. Prior to using theformulation of Example 2, MJ had exhibited under-eye skin that waspuffy, sensitive and quite dry. On day 0, MJ began using an amountapproximately equivalent to the size of a dime and used approximatelythat amount each morning and night on her skin. After one week, MJdescribed her under-eye skin as being less puffy. After two weeks, MJagain described her under-eye skin as being less puffy. After one month,MJ described her under-eye skin as being tighter looking and havingfewer small wrinkles such that the skin appeared to be smoother inappearance. MJ identified at least the following attributes as beingassociated with the formulation defined in Example 2: decreased skinwrinkles; improvement in skin tone; increased skin firmness; andincreased skin hydration.

Example 3. Composition with Acidified Fucoidan, Beta Glucan and Retinol

In accordance with a further embodiment of the present invention, acomposition is described having the components shown in Table 3. Themethodology employed in producing the composition using the amountsdescribed in Table 3 is generally as follows.

Method Sequence No. 1

In a first mixture, neutralized glycolic and salicylic acid solution(source: Dupont or Spectrum Chemical) was heated in a stainless steelcontainer to approximately 85 degrees Celsius. The seaweed complexconsisting of Ecklonia cava, Alteromonas maclodeii, and Astaxanthin(source: Unipex Innovations) was added to the heated glycolic acidmixture. The combined mixture was mixed for approximately 45 to 60minutes.

Polarized water was developed by adding tourmaline and obsidian (source:Soliance) to the distilled water. The beta glucan and fucoidan complex(source: Active Concepts, Marinova) was dissolved in one-third of thepolarized water. The dissolved beta glucan-fucoidan complex was added tothe glycolic acid mixture (previously described above) and the entiresolution continued to be stirred while the temperature was maintained atapproximately 85 degrees Celsius for approximately 30 minutes. Whilemaintaining mixing of the mixture, aqueous Aloe barbedensis leaf extract(source: Tri K Industries) was added and the entire mixture was allowedto cool for 30 minutes. Thereafter, hydrolyzed pearl nacre (source: RitaCorp.) and chitosan (source: Alfa Chem) were added to the cooledmixture. The entire mixture

TABLE 3 Components of an embodiment of the invention Se- Amount quence(% by No. Component weight) I Glycolic and salicylic acids (ratio: 8:1)10 (neutralized with ammonium hydroxide; ammonium glycolate, and sodiumlactate can also be added to obtain a preferable pH of ~4) I Seaweedcomplex containing Ecklonia cava, 5.5 Alteromonas maclodeii andAstaxanthin [ratio: 7:1.5:1.5] I Distilled water 14.8 I Tourmaline(0.15%) and volcanic obsidian (0.5%) 0.2 I Beta glucan (yeast andspecified medicinal fungi 8 extract combined in a 1:1 ratio) in a 1:1ratio with fucoidan complex I Aqueous Aloe barbedensis leaf extract 10 IHydrolyzed pearl nacre (1.5%) and chitosan 2.5 (1.0%) I Phospholipids 10II Glyceryl stearate, stearic acid, cetearyl alcohol, 20 ceteareth 20,isopropyl palmitate (each of these products is added at an equal amount)II Tocotrienol, tocopheryl acetate, niacinamide, 6 retinol complex(ratio of these products: 3:1.5:1.5:0.5) II Aqueous extract of Vitisvinifera, Chamomile 2.5 matricaria, Echinacea augustifolia, Panaxginseng, Glycine soja, allantoin (each of these products is added at anequal amount) III Complex of butylene glycol, phenoxyethanol, 2.5caprylyl glycol, sorbic acid, peg8/SMDI copolymer (ratio of theseproducts: 1.5:0.5:0.25:0.25:0.25) III Aqueous superoxide dismutaseliposomes 8was allowed to cool to approximately 30 degrees Celsius. Thereafter,phospholipids (source: Arch Personal Care) were added to the cooledmixture.

Method Sequence No. 2

In a further mixture, glycerylstearate, stearic acid, cetearyl alcohol,ceteareth 20, and isopropyl palmitate complex (source: Hallstar Corp.)were heated to 75 degrees Celsius in a 200 kg. stainless steel vat. Themixture was mixed by continuous stirring for 60 minutes. Separately, theremaining two-thirds of polarized water (as described above) was used todissolve the tocotrienol-retinol complex (source: Arch Personal Care).The tocotrienol-retinol complex was allowed to dissolve in the polarizedwater for one hour. Thereafter, aqueous extracts of Vitis vinifera,Chamomile matricaria, Echinacea augustifolia, Panax ginseng, Glycinesoja, and allantoin (source: Active Organics) were added to thetocotrienol-retinol complex.

Method Sequence No. 3

In a further mixture, butylene glycol, phenoxyethanol, caprylyl glycol,sorbic acid, and peg8/SMDI copolymer were combined to make a complex(source: International Specialty Products). Thereafter, this complex wasadded to the glyceryl stearate complex mixture described above, theglyceryl stearate complex having been maintained at 75 degrees Celsius.Thereafter, the ascorbyl polypeptide-tocotrienol complex, which hadpreviously been mixed with the aqueous extracts described above, wasadded and agitation of the mixture continued at approximately 75 degreesCelsius. Thereafter, the entire mixture was cooled down to approximately30 degrees Celsius.

Thereafter, the mixture developed from Method Sequence No. 1 was addedto the mixture. The mixture was allowed to cool down to approximately 20degrees Celsius and liposomal superoxide dismutase (source: ArchPersonal Care) was added. In a modification to the above, the seaweedcomplex can be present as 3.5% of the formulation instead of 5.5% asdescribed in Table 3. Further, the beta glucan and fucoidan complex canbe present as 10% of the formulation instead of 8% as described in Table3.

Testing Efficacy of Example 3

To test the efficacy of the mixture described in Example 3, the mixturewas used by human subjects to determine the effect on the appearance oftheir skin. The results routinely showed that the mixture described inExample 3 improved the appearance of the skin of human subjects.

Serving as an example, CO, a female between the age of 30-40 years ofage, used the formulation defined in Example 3. Prior to using theformulation of Example 3, CO had exhibited oily skin that was prone toacne breakouts. Further, CO described that her skin was rough, and thatskin pores were visible. Further, CO described that her skin showed anappearance of acne scarring. On day 0, CO began using an amountapproximately equivalent to the size of a dime and used approximatelythat amount each night on her skin. After one week, CO described herskin as having faded acne scar ring. After two weeks, CO described thather skin appeared to be more radiant and glowing in appearance. Afterone month, CO described her skin as being firmer and that the acnebreakouts had stopped. CO identified at least the following attributesas being associated with the formulation defined in Example 3: decreasedskin wrinkles; improvement in skin tone; increased skin firmness; andincreased skin hydration.

Example 4. Composition with Acidified Fucoidan and Beta Glucan

In accordance with a further embodiment of the present invention, acomposition is described having the components shown in Table 4. Themethodology employed in producing the composition using the amountsdescribed in Table 4 is generally as follows.

Tourmaline and volcanic obsidian (source: Soliance) were dissolved intodistilled water. Ulva lactuta, fucoidan (source: Marinova), beta glucan(source: Arch Personal Care) were added to above polarized water andmixture was heated to approximately 80 degrees Celsius and stirred forapproximately 40 minutes.

Neutralized glycolic acid, as disclosed herein, was added to the abovemixture, and stirred at approximately 80 degrees Celsius forapproximately another 30 minutes. Thereafter, Aloe barbedensis leafextract (source: Tri-K) and aqueous extract of Camellia sinensis,Gentelia

TABLE 4 Components of an embodiment of the invention Se- Amount quence(% by No. Component weight) I Aqueous Aloe barbedensis leaf extract 45 IDistilled water 40.8 I Tourmaline, volcanic obsidian 0.2 I Glycolic andsalicylic acids (ratio 8:1) (neutralized 6 with ammonium hydroxide;ammonium glycolate, and sodium lactate can also be added to obtain apreferable pH of ~4) I Fucoidan, beta glucan, Ulva lactuta (ratio:5:5:1.5) 4 II Aqueous extract of Camellia sinensis, Centella 1.5asiatica, Chamomile matricaria, Echinacea augustifolia, Ginko biloba(these extracts are present in an equal amount) III Complex of butyleneglycol, allantoin, 2.5 phenoxyethanol, caprylyl glycol, sorbic acid(ratio: 1.5:0.5:0.25:0.25:0.25)asiatica, Chamomile matricaria, Echinacea augustifolia, and Ginko biloba(source: Active Organics) as detailed in the corresponding Table, wereadded and the entire mixture was stirred for approximately another 10minutes.

At this stage any of a variety of surfactants can be incorporated toconstitute an effective cleansing composition focusing on the above keyingredients. Thereafter, butylene glycol, allantoin, phenoxyethanol,caprylyl glycol, sorbic acid (source: International Specialty Products)were added and the entire mixture was stirred for approximately another10 minutes. The entire mixture was then cooled to room temperature.

Testing Efficacy of Example 4

To test the efficacy of the mixture described in Example 4, the mixturewas used by human subjects to determine the effect on the appearance oftheir skin. The results routinely showed that the mixture described inExample 4 improved the appearance of the skin of human subjects.

Serving as an example, MT, a male under the age of 30 used theformulation defined in Example 4. Prior to using the formulation ofExample 4, MT had exhibited slightly acnied skin that included a smallamount of wrinkling. On day 0, MT began applying the formulation definedin Example 4 to his skin using a cotton pad soaked in the formulationdefined in Example 4. After one week, MT described his skin as appearingclearer with a less dull appearance. After two weeks, MT described hisskin as having less breakouts of acne. After one month, MT described hisskin as appearing brighter, clearer, and tighter. MT identified at leastthe following attributes as being associated with the formulationdefined in Example 4: increased skin firmness; improved skin tone, andsmoother and brighter skin appearance.

Example 5. Composition with Acidified Fucoidan

In accordance with a further embodiment of the present invention, acomposition is described having the components shown in Table 5. Themethodology employed in producing the composition using the amountsdescribed in Table 5 is generally as follows.

Method Sequence No. 1

In a first mixture, neutralized glycolic acid (source: Dupont orSpectrum Chemical), salicylic acid (source: Spectrum), tourmaline andvolcanic obsidian (source: Soliance) was heated

TABLE 5 Components of an embodiment of the invention Se- Amount quence(% by No. Component weight) I Glycolic and salicylic acids (ratio 8:1)(neutralized 12.8 with ammonium hydroxide; ammonium glycolate, andsodium lactate can also be added to obtain a preferable pH of ~4) ITourmaline (0.15%) and volcanic obsidian (0.5%) 0.2 I Kaolin andbentonite (ratio of these products: 0.6:0.3) 26 I Beta glucan (yeast andspecified medicinal fungi 10 extract combined in a 1:1 ratio) in a 1:1ratio with fucoidan complex, Ulva lactuta [5:5:1.5] I Undariapinnatifida 4 I Diatomite silica, n-acetyl glucosamine, hydrolyzed 2.5pearl nacre, and chitosan (ratio of these products: 1:1:0.25:0.25) IAqueous Aloe barbedensis leaf extract 10 I Echinacea augustifolia andPanax ginseng (ratio of 2 these products: 1:1) II Stearic acid, cetearylalcohol, and ceteareth 20 30 complex in equal parts (each of theseproducts is added at an equal amount) III Complex of phenoxyethanol,caprylyl glycol, sorbic 2.5 acid (ratio of these products: 1.5:0.5:05)in a stainless steel container to approximately 85 degrees Celsius. Theseaweed complex consisting of ulva lactuta (source: Unipex Innovations),beta glucan-fucoidan complex (source: Biothera, Marinova), and Undariapinnatifida (source: Marinova) were added to the heated glycolic acidmixture. The combined mixture was agitated for approximately 30 minutes.Diatomite silica, n-acetyl glucosamine, hydrolyzed pearl nacre (source:Rita Corp.), and chitosan (source: Alfa Chem) were added to the abovemixture.

Kaolin and bentonite (source: Xenex Labs; Vancouver, British Columbia]were separately mixed and added to the above mixture. While maintainingmixing of the mixture, aqueous Aloe barbedensis leaf extract (source:Tri K Industries), Echinacea augustifolia, and Panax ginseng (source:Active Organics) were added.

Method Sequence No. 2

Thereafter, and separately, stearic acid, cetearyl alcohol, andceteareth 20 complex (source: Hallstar Corp.) were heated toapproximately 75 degrees C., stirring for approximately minutes.

Method Sequence No. 3

In a further mixture, phenoxyethanol, caprylyl glycol, and sorbic acid(source: International Specialty Products) were combined to make acomplex. Thereafter, this complex was added to the stearic acid complexdescribed above, the stearic complex having been maintained atapproximately 75 degrees Celsius. Thereafter, the entire mixture wascooled down to approximately 30 degrees Celsius. Thereafter, the mixturedeveloped from Method Sequence No. 1 (see above) was added to themixture. The mixture was allowed to cool to approximately 20 degreesCelsius.

In a modification to the above, the beta glucan complex can be presentas 12% of the formulation instead of 10% as described in Table 5.Further, the Undaria pinnatifida can be present at 2% instead of 4% asdescribed in Table 5.

Testing Efficacy of Example 5

To test the efficacy of the mixture described in Example 5, the mixturewas used by human subjects to determine the effect on the appearance oftheir skin. The results routinely showed that the mixture described inExample 5 improved the appearance of the skin of human subjects.

Serving as an example, JT, a female between the age of 30-40, used theformulation defined in Example 5. Prior to using the formulation ofExample 5, JT had exhibited skin conditions that included acne and roughspots. On day 0, JT began using an amount approximately equivalent tothe size of a quarter and used approximately twice that amount twice aweek. After one week, JT described her skin as having fewer breakouts ofacne. After two weeks, JT described her skin as being clearer. After onemonth, JT described her skin as appearing smoother. JT identified atleast the following attributes as being associated with the formulationdefined in Example 5: increased smoothness of the skin, increasedluminosity of the skin, increased firmness of the skin, increasedtautness of the skin, and less irritation and skin-associatedinflammation.

Example 6. Serum Composition

The methodology employed in producing the non-acidified serumcomposition using the amounts described in Table 6 is generally asfollows.

Method Sequence No. 1

Polarized water was developed by adding tourmaline and obsidian (source:Soliance) to the distilled water. The seaweed complex consisting ofphytoplankton extract (source: Canadian Pacific Phytoplankton), Fucusvesiculosus extract (source: Xenex), ecklonia cava (source: JP Renew;San Francisco, Calif.) was dissolved into one-half of the distilledwater, heated to approximately 85 degrees Celsius. The combined mixturewas then stirred for approximately 45 minutes to 60 minutes. The betaglucan and fucoidan complex (source: Biothera, Marinova) and vegetalastaxanthin (source: Unipex Innovations) was dissolved in the seaweedcomplex-distilled water mixture (previously described above). The heatedmixture continued to be stirred while the temperature was maintained atapproximately 85 degrees Celsius for a minimum of approximately 30minutes. The entire mixture was allowed to cool to

TABLE 6 Components of an embodiment of the invention Se- Amount quence(% by No. Component weight) I Distilled water 40.8 I Tourmaline,volcanic obsidian [1:.5] 0.2 I Phytoplankton extract, Fucus vesiculosus,6 extract, Ecklonia cava complex [1:1:.5:.5] I Beta glucan (yeast andspecified medicinal fungi 8 extract combined in a 1:1 ratio), fucoidan,vegetal astaxanthin complex [5:5:1.5] I Hydrolyzed pearl nacre, chitosan[1:.5] 1.5 I Phospholipids, sodium pCA [1:.5] 8 II Magnesium ascorbylphosphate, tocotrienol, 25 niacinamide, tocopheryl acetate,ergocalciferol complex [10:1:.5:.5:.5] II Camellia sinensis,epigallocatechin (EGCG), 4 ellagic acid, l-arginine [2:1:.5:.5] IIIComplex of butylene glycol, phenoxyethanol, 3.5 carprylyl glycol, sorbicacid, peg8/SMDI copolymer [2:1:.5:.5:.5] III Sodium citrate, tetrasodiumEDTA [1:.5] 3to approximately 30 degrees Celsius. Thereafter, hydrolyzed pearl nacre(source: Active Concepts) and chitosan (source: Alfa Chem) were added tothe cooled mixture. Thereafter, phospholipids (source: Arch PersonalCare) and sodium hyaluronate (source: Tri-K Industries) were added tothe cooled mixture.

Method Sequence No. 2:

In a further mixture, a complex comprising magnesium ascorbyl phosphate(source: Optima Specialty; Huntington, Conn.) with tocotrienol,niacinamide, tocopheryl acetate, ergocalciferol (source: Arch PersonalCare) was mixed into the remaining one-half of polarized water andheated to approximately 70 degrees Celsius. This mixture was allowed todissolve in the polarized water for one hour. Thereafter, Camelliasinensis (source: Active Organics), epigallocatechin (EGCG) (source: DSMNutritional Products; Belvedere, N.J.), ellagic acid (source: DSM), and1-arginine (source: Alpha Chem) were added to the ascorbylpolypeptide-tocotrienol complex.

Method Sequence No. 3

In a further mixture, butylene glycol, phenoxyethanol, caprylyl glycol,sorbic acid, and peg8/SMDI copolymer (source: International SpecialtyProducts) are combined in the ratio specified in the Table 6 above tomake a complex. Thereafter, this complex was added to the magnesiumascorbyl-tocotrienol mixture described above in Method Sequence No. 2,the magnesium ascorbyl-tocotrienol having been maintained atapproximately 70 degrees Celsius. Thereafter sodium citrate andtetrasodium EDTA (source: Xenex) was added. The mixture was then stirredfor approximately 15 minutes, while maintaining at approximately 70degrees Celsius. Thereafter, the entire mixture was cooled down toapproximately 30 degrees Celsius. Thereafter, the mixture developed fromMethod Sequence No. 1 was added to the mixture. The mixture was allowedto cool down to approximately 20 degrees Celsius.

In a modification to the above, the phytoplankton extract can be presentas 2% of the formulation instead of 6% as described in Table 6. Further,the bet glucan complex can be present at 12% instead of 8% as describedin Table 6.

Testing Efficacy of Example 6

To test the efficacy of the mixture described in Example 6, the mixturewas used by human subjects to determine the effect on the appearance oftheir skin. The results routinely showed that the mixture described inExample 6 improved the appearance of the skin of human subjects.

Serving as an example, TK, a female over the age of 40 used theformulation defined in Example 6. Prior to using the formulation ofExample 6, TK had exhibited sensitive skin conditions and her skin wassun-damaged. On day 0, TK began using an amount equivalent to the sizeof a dime of the formulation in Example 6 on a daily basis. After oneweek, TK described her skin as appearing more refreshed. After twoweeks, TK described her skin as appearing less irritated or red ascompared with before use of the formulation. After one month, TKdescribed her skin as appearing clearer, and more firm with less wrinklelines. TK identified at least the following attributes as beingassociated with the formulation defined in Example 6: increasedsmoothness (diminished appearance of wrinkles); increased luminosity;increased firmness; increased tautness; and less irritation andskin-associated inflammation.

Example 7. Effect of Formulation 7 on Human Skin

An experimental protocol (DCS-02-11) was designed to test the effect ofa formulation that was similar to that detailed in Example 3 herein. Theexperimental protocol was carried out through Draelos ConsultingServices of North Carolina. More particularly, the following formulation(referred to herein as Formulation 7; detailed in Table 7 herein) wasprepared using methodology described herein.

This was a single-site investigator blinded study to evaluate, in part,the efficacy of Formulation 7 with respect to improving facialappearance. The subjects were compared to baseline to provide ahistorical control. Each subject applied the skin care product regimentwice daily and no other skin care products were utilized. Assessmentsconsisted of investigator-led evaluations, subject evaluations, andphotography of the face at each time point (baseline and 2 weeks).Noninvasive procedures of transepidermal water loss, comeometry, andskin elasticity were performed at each time point. Subjects were seen atthe following intervals: Baseline and Week 2.

TABLE 7 Components of an embodiment of the invention (Formulation 7) Se-Amount quence (% by No. Component weight) I Glycolic and salicylic acids(ratio: 8:1) 10 (neutralized with ammonium hydroxide; ammoniumglycolate, and sodium lactate can also be added to obtain a preferablepH of ~4) I Seaweed complex containing Undaria pinnatifida 5.5 andAstaxanthin [ratio: 7:5] I Distilled water 14.8 I Tourmaline (0.15%) andvolcanic obsidian (0.5%) 0.2 I Beta glucan (yeast and specifiedmedicinal fungi 8 extract combined in a 1:1 ratio) in a 1:1 ratio withfucoidan complex I Aqueous Aloe barbedensis leaf extract 10 I Hydrolyzedpearl nacre (1.5%) and chitosan 2.5 (1.0%) I Phospholipids 10 IIGlyceryl stearate, stearic acid, cetearyl alcohol, 20 ceteareth 20,isopropyl palmitate (each of these products is added at an equal amount)II Tocotrienol, tocopheryl acetate, niacinamide, 6 Chrithmum maritimumcomplex (ratio of these products: 3:1.5:1.5:0.5) II Aqueous extract ofVitis vinifera, Chamomile 2.5 matricaria, Echinacea augustifolia, Panaxginseng, Glycine soja, allantoin (each of these products is added at anequal amount) III Complex of butylene glycol, phenoxyethanol, 2.5caprylyl glycol, sorbic acid, peg8/SMDI copolymer (ratio of theseproducts: 1.5:0.5:0.25:0.25:0.25) III Aqueous superoxide dismutaseliposomes 8

Female subjects 30-70 years of age of all Fitzpatrick skin types withmild to moderate photoaging were chosen for this experimental protocol.Inclusion criteria for this experimental protocol were as follows:

-   -   1. Subjects must only apply the study product twice daily as        directed to the entire face.    -   2. Subjects must be between 30 and 70 years of age.    -   3. Subjects must possess mild to moderate facial photoaging.    -   4. Subjects must have no medically relevant skin disease on the        face.    -   5. Women of childbearing potential must be willing to use a form        of birth control during the study. For the purpose of this        study, the following were considered acceptable methods of birth        control: oral contraceptives, Norplant®, Depo-Provera®, double        barrier methods (e.g., condom and spermacide) and abstinence.    -   6. Subjects must provide written informed consent.

Exclusion criteria for this experimental protocol were as follows:

-   -   1. Any dermatological disorder, which in the investigator's        opinion, may interfere with the accurate evaluation of the        subject's facial skin.    -   2. Subjects who spend excessive time out in the sun.    -   3. Subjects who have demonstrated a previous hypersensitivity        reaction to any of the ingredients of the study products.    -   4. Subjects who are pregnant, breast feeding, or planning a        pregnancy.    -   5. Subjects with clinically significant unstable medical        disorders.    -   6. Subjects who are unwilling or unable to comply with the        requirements of the protocol.    -   7. Subjects who are using topical or OTC medications or creams        to the face, including topical corticosteroids.    -   8. Subjects who have undergone a cosmetic surgical treatment to        the face within the past year.    -   9. Subjects who use any prescription or non-prescription        medications that might interfere with the topical study product        in the opinion of the investigator.    -   10. Subjects who have history of a psychological illness or        condition that would interfere with their ability to understand        and follow the requirements of the study.    -   11. Subjects who have skin unsuitable for noninvasive        assessment.

Experimental Analysis of Formulation 7 at 2-Week Time Point

The following assessments were made at the 2-week time-point:Elasticity: A trend toward improved skin firmness was seen after 2 weeksof product use with a p value of 0.057. This is demonstrated by thedecrease in skin elasticity observed from 6.39 at baseline to 5.05 after2 weeks of product use (see: Table 8 herein). Briefly, the elasticityreadings were conducted using a Dermalab Elasticity Machine. Thismachine uses suction to develop stress and relaxation curves that arecomputer analyzed to arrive at the final readings (as provided herein).

Investigator Assessment

The investigator assessed a statistically significant improvement inskin smoothness (p=0.001) and a statistically significant improvement inskin dryness (p=0.002) after 2 weeks of product use (see Tables 9A and9B herein). The investigator assessment readings represent an ordinalscale where O=none; 1=minimal; 2=mild; 3=moderate; and 4=severe.

Subject Assessment

Further, a trend was seen to an improvement in overall appearance(p=0.056) (see Tables 10A and 10B herein). The subject assessmentreadings represent an ordinal scale where O=none; 1=minimal; 2=mild;3=moderate; and 4=severe.

Transepidennal Water Loss (TEWL)

Further, there was a decrease in TEWL after 2 weeks of product use fromthe baseline value of 12.81 to 12.03 at week 2 (see Table 11 herein).The TEWL readings were conducted with a Dermalab Evaporimeter. Theprobes therein use two humidity meters at a known distance above theskin to determine the mg of water vapor lost per cm per minute.

TABLE 8 Elasticity Measurements at 2-week Time-point Subject Baselineelasticity Week 2 elasticity No. measurement measurement 1 4.5 3.5 2 2.42.4 3 4.4 2.6 4 3.4 2.9 5 4.9 4.3 6 17.4 10.9 7 12.7 7.1 8 3.9 2.4 9 2.22 10 2 2 11 5.5 6.2 12 5.5 3.5 13 6 9.9 14 6.7 4.8 15 14.3 11.3 Average6.39 5.05

TABLE 9A Baseline Poor Subject Lack of Fine Skin Lack of Overall #Unblind Firmness Wrinkles Lines Texture Smoothness Dryness Appearance 1A 2 2 2 2 2 2 2 2 A 2 2 2 2 2 2 2 3 A 3 3 2 3 2 2 3 4 A 3 3 3 3 2 2 3 5A 3 3 3 3 2 2 3 6 A 4 4 4 4 4 4 4 7 A 3 3 3 3 2 2 3 8 A 2 2 2 2 2 2 2 9A 2 2 2 2 2 2 2 10 A 2 2 2 2 2 2 0 11 A 4 4 4 4 4 4 4 12 A 4 4 4 4 4 4 413 A 4 4 4 4 4 4 4 14 A 4 3 3 3 3 3 3 15 A 3 2 2 3 3 3 3 Mann- Mean A2.93 2.87 2.80 2.93 2.73 2.67 2.80 Whitney Baseline two tailed A pairedA v. Baseline p = Z-score =

TABLE 9B Baseline Poor Subject Lack of Fine Skin Lack of Overall #Unblind Firmness Wrinkles Lines Texture Smoothness Dryness Appearance 1A 1 2 2 2 1 1 2 2 A 2 2 2 1 1 1 2 3 A 3 3 2 3 1 1 2 4 A 3 3 3 3 1 1 2 5A 3 3 3 3 2 2 3 6 A 4 4 4 4 3 3 4 7 A 2 1 1 2 1 1 2 8 A 2 2 2 2 1 1 2 9A 2 2 2 2 1 1 2 10 A 2 2 1 1 1 1 2 11 A 4 4 4 4 2 2 4 12 A 4 4 4 4 2 2 413 A 4 4 4 4 2 2 4 14 A 3 3 3 3 2 2 3 15 A 3 2 2 3 3 3 3 Mann- Mean A2.80 2.73 2.60 2.73 1.60 1.60 2.80 Whitney Baseline 2.93 2.87 2.80 2.932.73 2.67 2.80 two tailed A paired A v. 0.727 0.710 0.584 0.648 0.0010.002 0.584 Baseline p = Z-score = −0.35 −0.37 −055 −0.46 −3.21 −3.09−0.55

TABLE 10A Baseline Poor Subject Lack of Fine Skin Lack of Overall #Unblind Firmness Wrinkles Lines Texture Smoothness Dryness Appearance 1A 0 0 0 2 3 4 3 2 A 3 1 1 3 3 4 3 3 A 3 3 3 2 2 2 2 4 A 2 2 2 3 3 2 1 5A 1 3 3 3 3 3 3 6 A 2 2 2 2 2 3 3 7 A 2 1 1 3 1 2 3 8 A 1 1 2 1 2 2 1 9A 2 0 0 3 3 1 1 10 A 1 1 1 0 0 1 1 11 A 2 2 2 1 1 2 2 12 A 2 3 3 3 3 2 313 A 1 2 2 2 2 1 2 14 A 3 2 3 3 3 0 3 15 A 2 3 3 3 2 3 3 Mann- Mean A1.80 1.73 1.87 2.27 2.20 2.13 2.27 Whitney Baseline two tailed A pairedA v. Baseline p = Z-score =

TABLE 10B Week 2 Poor Subject Lack of Fine Skin Lack of Overall #Unblind Firmness Wrinkles Lines Texture Smoothness Dryness Appearance 1A 0 0 0 0 1 3 1 2 A 2 1 2 3 3 3 2 3 A 3 3 3 3 2 2 2 4 A 2 2 2 1 1 1 1 5A 2 2 2 2 2 2 2 6 A 3 3 3 3 2 2 2 7 A 2 1 1 3 3 0 3 8 A 1 0 0 0 1 2 1 9A 2 0 1 0 2 1 1 10 A 0 1 1 1 1 1 1 11 A 2 3 3 3 3 2 2 12 A 1 1 1 0 1 1 113 A 1 2 2 2 2 0 1 14 A 2 2 3 3 2 0 2 15 A 0 1 1 3 3 2 2 Mann- Mean A1.53 1.47 1.67 1.80 1.93 1.47 1.67 Whitney Baseline 1.80 1.73 1.87 2.272.20 2.13 2.27 two tailed A paired A v. 0.495 0.479 0.576 0.386 0.3030.120 0.056 Baseline p = Z-score = −0.68 −0.71 −0.56 −0.87 −1.03 −1.56−1.91

TABLE 11 Transepidermal Water Loss (TEWL) Measurements at 2-weekTime-point Subject Baseline TEWL Week 2 TEWL No. measurement measurement1 18.2 11.5 2 13.7 5.7 3 14.4 13.5 4 12.2 13.3 5 15.8 13.2 6 5.5 11.1 712.3 5 8 8.9 7.9 9 8.4 33.3 10 10.7 9.3 11 10.2 3.1 12 16.1 7.9 13 16.518.9 14 16.2 15 15 13.1 11.8 Average 12.81 12.03

Example 8. Composition with Acidified Fucoidan, Beta Glucan and Natural(Marine) Retinol

In accordance with a further embodiment of the present invention, acomposition is described having the components shown in Table 12.

TABLE 12 Components of an embodiment of the invention Se- Amount quence(% by No. Component weight) I Shikimic, glycolic, and salicylic acids(1.5:1:.25) (neutralized with 2.75 ammonium hydroxide; ammoniumglycolate, sodium lactate can also be added to obtain a preferable pH of~4) I Seaweed complex containing Fucus vesiculosus, Ecklonia cava, 4.25phytoplankton, Eugenia gracilis and Astaxanthin (ratio: 1:1:1:1:.25) IDistilled water 39.8 I Tourmaline 0.2 I Beta glucan (yeast and specifiedmedicinal fungi extract combined in a 2.0 1:1 ratio) in a 1:1 ratio withfucoidan complex I Aqueous Aloe barbadensis extract; polygonummultiforum, horsetail, 9.0 pumpkin, hops, peppermint (5:1:1:1:.75:.25) IPea protein, inulin (1.5:.5) 2.0 II Glyceryl stearate, stearic acid,cetearyl alcohol, ceteareth 20, isopropyl 2.5 palmitate complex (each ofthese products is added at an equal amount) II Meadowfoam oil,phospholipids, Helianthus annuus oil, Nigella sativa 10.25 oil,Azadirachta indica oil, hemp, cedar, Ricinus communis oil (ratio:4:2:1:1:1:1:.25) II Niacinamide, tocotrienol, tocopheryl acetate,curcumin, Chrithmum 7.5 maritum complex (ratio of these products:3:1.5:1.5:1:0.5) II N-acetyl carnitine, taurine, alanine, thymol,choline, inositol, caffeine, 6.75 panthenol (ratio:2:1:1:1:.5:.5:.5:.25] II Aqueous extract of Vitis vinifera, Humuluslupulus, Chamomile 5.0 matricaria, Echinacea augustifolia, Panaxginseng, Zingiber officinale, allantoin (each of these products is addedat an equal amount) III Complex of butylene glycol, phenoxyethanol,caprylyl glycol, sorbic 3.5 acid, peg8/SMDI copolymer, saccromyceslysate (these products are added at the following ratio:1.5:1:0.25:0.25:0.25:0.25) III Superoxide dismutase,methylsulfonylmethane, teprenone (ratio of 8.0 6:1.5:.5)

The composition of Table 12 was tested in subjects (n=5). The subjectsapplied the composition 2× daily for eight (8) weeks. After the eight(8) weeks, the subjects self-reported on the benefits of the treatment,as described below.

Subjects that had a dry and/or irritated scalp reported one or more ofthe following benefits to their scalp:

-   -   Increased comfort to the scalp    -   Increased moisture/hydration to the scalp    -   Increased tingling of the scalp    -   Reduced dryness of the scalp    -   Reduced flaking of the scalp    -   Reduced irritation of the scalp    -   Reduced redness of the scalp    -   Reduced scaling of the scalp

In addition, the composition of claim 12 was effective in reducing hairloss and/or regrowing hair, in certain subjects that were experiencinghair loss. Some individuals experienced both reduction in hair lossand/or regrowing of hair, as well as one or more of the benefits to thescalp, as described above.

Details of the self-reported benefits of each subject is provided below.

Subject 1

-   -   Possible reduction in redness of the scalp    -   Possible reduction in scaling of the scalp    -   Reduction in hair loss    -   Possible hair re-growth

Subject 2

-   -   Increased moisture to the scalp

Subject 3

-   -   Increased comfort to the scalp    -   Increased moisture/hydration to the scalp    -   Reduced irritation of the scalp    -   Reduced flaking of the scalp

Subject 4

-   -   Increased moisture/hydration of the scalp    -   Increased comfort to the scalp    -   Increased tingling of the scalp    -   Reduction in hair loss

Subject 5

Subject suspended use after a short period due to an illness. During theshort period the subject applied the composition, she/he did notexperience a noticeable change.

Example 9. Gene Chip Experiments

To examine the effect of formulations described herein on differentialgene expression, gene chip experiments were conducted through the KUGenomic Facility (Lawrence, Kans.). Briefly, SH-SYSY neuroblastoma cellswere cultured for 48 hours, and then treated with 1) Formulation 9 (1%Undaria pinnatifida based fucoidan extract-beta glucan combination (1:1ratio) dissolved in water; 2) water (neg. ctrl for #1); 3) Formulation 9dissolved in 20% glycolic acid; and 4) 20% glycolic acid (neg. ctrl for#3). The treatments las ted for 12 hours, after which total RNA wasextracted from the treated cells. The RNA samples were then used tohybridize to the Human Genome U133 2.0 GeneChip from Affymetrix, whichis designed to interrogate all currently known human genes. Afterhybridization, the GeneChips were scanned and GeneChip data generated.After a series of bioinformatics analyses, genes showing significantchanges (treatment #1 compared to #2; also #3 to #4) after the extracttreatments were identified. A subset of these genes, that are known tobe related to skin function, were identified as shown in Table 13herein.

While specific embodiments of the invention have been described, suchembodiments should be considered illustrative of the invention only andnot as limiting the invention as construed in accordance with theaccompanying claims.

TABLE 13 Skin-related Genes Upregulated at 12 Hour Timepoint Gene FoldSymbol Gene Name Change Function Formulation 9 in Glycolic Acid Col18A1collagen, type XVIII, 8.91 collagen and alpha 1 collagen fibrilorganization ADAM11 ADAM metallopeptidase 6.33 metallopeptidase domain11 activity ADAMTS1 ADAM metallopeptidase 4.8 metallopeptidase withthrombospondin activity type 1 motif, 1 CEP57 centrosomal protein 4.44fibroblast growth 57 kDa factor receptor signaling pathway EGFRepidermal growth factor 4.39 epidermal growth receptor factor receptorsignaling pathway Formulation 9 in water GDF15 growth differentiation3.07 growth factor factor 15 activity CEBPB CCAAT/enhancer 2.22 immuneresponse binding protein (C/EBP), beta LUM lumican 1.82 proteinaceousextracellular matrix

While preferred embodiments of the present invention have been shown anddescribed herein, it will be obvious to those skilled in the art thatsuch embodiments are provided by way of example only. Numerousvariations, changes, and substitutions will now occur to those skilledin the art without departing from the invention. It should be understoodthat various alternatives to the embodiments of the invention describedherein may be employed in practicing the invention. It is intended thatthe following claims define the scope of the invention and that methodsand structures within the scope of these claims and their equivalents becovered thereby.

1. (canceled)
 2. A composition comprising: an effective amount of aseaweed complex containing Fucus vesiculosis, Ecklonia cava,phytoplankton, Eugenia gracilis, and Astaxanthin; an effective amount ofa beta glucan and fucoidan complex; and an effective amount of aformulation comprising aqueous Aloe barbadensis extract, polygonummultiforum, horsetail, pumpkin, hops and peppermint.
 3. The compositionof claim 2, further comprising an effective amount of a formulationcomprising meadowfoam oil, phospholipids (algal), Helianthus annuus oil,Nigella sativa oil, Azadirachta indica oil, hemp, cedar, and Ricinuscommunis oil.
 4. The composition of claim 2, further comprising aneffective amount of a formulation comprising niacinamide, tocotrienol,tocopheryl acetate, curcumin, and Chrithmum maritum complex.
 5. Thecomposition of claim 2, further comprising an effective amount of aformulation comprising a complex of butylene glycol, phenoxyethanol,caprylyl glycol, sorbic acid, and saccharomyces lysate.
 6. Thecomposition of claim 2, wherein the ratio of Fucus vesiculosis, Eckloniacava, phytoplankton, Eugenia gracilis, and Astaxanthin is approximately1:1:1:0.25.
 7. The composition of claim 2, wherein the ratio of betaglucan and fucoidan complex is approximately 1:1.
 8. The composition ofclaim 2, wherein the ratio of aqueous Aloe barbadensis extract,polygonum multiforum, horsetail, pumpkin, hops and peppermint isapproximately 5:1:1:1:0.75:0.25.
 9. The composition of claim 3, whereinthe ratio of meadowfoam oil, phospholipids (algal), Helianthus annuusoil, Nigella sativa oil, Azadirachta indica oil, hemp, cedar, andRicinus communis oil is approximately 4:2:1:1:1:1:0.25.
 10. Thecomposition of claim 4, wherein the ratio of niacinamide, tocotrienol,tocopheryl acetate, curcumin, and Chrithmum maritum complex isapproximately 3:1.5:1.5:1:0.5.
 11. The composition of claim 5, whereinthe ratio of butylene glycol, phenoxyethanol, caprylyl glycol, sorbicacid, and saccharomyces lysate is approximately1.5:1:0.25:0.25:0.25:0.25.
 12. The composition of claim 2, furthercomprising an effective amount of shikimic, glycolic, and salicylicacids.
 13. The composition of claim 12, wherein the ratio of shikimic,glycolic, and salicylic acids is approximately 1.5:1:0.25.
 14. Thecomposition of claim 2, further comprising an effective amount of peaprotein and inulin.
 15. The composition of claim 2, further comprisingan effective amount of a glyceryl stearate, stearic acid, cetearylalcohol, ceteareth 20, and isopropyl palmitate complex.
 16. Thecomposition of claim 2, further comprising an effective amount ofN-acetyl carnitine, taurine, alanine, thymol, choline, inositol,caffeine, and panthenol.
 17. A method of treating a condition associatedwith the scalp of a subject, the method comprising administering aneffective amount of the composition of claim 2 to the scalp of thesubject.
 18. The method of claim 17, wherein the composition is appliedat least twice daily.
 19. The method of claim 17, wherein thecomposition is applied twice daily for at least one week.